Literature DB >> 24382744

Stereotactic body radiotherapy: a critical review for nonradiation oncologists.

John P Kirkpatrick1, Christopher R Kelsey, Manisha Palta, Alvin R Cabrera, Joseph K Salama, Pretesh Patel, Bradford A Perez, Jason Lee, Fang-Fang Yin.   

Abstract

Stereotactic body radiotherapy (SBRT) involves the treatment of extracranial primary tumors or metastases with a few, high doses of ionizing radiation. In SBRT, tumor kill is maximized and dose to surrounding tissue is minimized, by precise and accurate delivery of multiple radiation beams to the target. This is particularly challenging, because extracranial lesions often move with respiration and are irregular in shape, requiring careful treatment planning and continual management of this motion and patient position during irradiation. This review presents the rationale, process workflow, and technology for the safe and effective administration of SBRT, as well as the indications, outcome, and limitations for this technique in the treatment of lung cancer, liver cancer, and metastatic disease.
© 2013 American Cancer Society.

Entities:  

Keywords:  intensity-modulated radiotherapy; liver cancer; lung cancer; normal tissue complications; oligometastases; radiosurgery; spine metastases; stereotactic body radiotherapy

Mesh:

Year:  2013        PMID: 24382744     DOI: 10.1002/cncr.28515

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Stereotactic Body Radiation Therapy: A useful weapon in anticancer treatment.

Authors:  M Scorsetti
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-23

Review 2.  Endoluminal and Interstitial Brachytherapy for the Treatment of Gastrointestinal Malignancies: a Systematic Review.

Authors:  Sujana Gottumukkala; Vasu Tumati; Brian Hrycushko; Michael Folkert
Journal:  Curr Oncol Rep       Date:  2017-01       Impact factor: 5.075

3.  A 4D ultrasound real-time tracking system for external beam radiotherapy of upper abdominal lesions under breath-hold.

Authors:  Dwi Seno Kuncoro Sihono; Lena Vogel; Christel Weiß; Johannes Thölking; Frederik Wenz; Frank Lohr; Judit Boda-Heggemann; Hansjörg Wertz
Journal:  Strahlenther Onkol       Date:  2016-12-05       Impact factor: 3.621

4.  Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy : Complications and risk factors.

Authors:  Konrad Mohnike; Steffen Wolf; Robert Damm; Max Seidensticker; Ricarda Seidensticker; Frank Fischbach; Nils Peters; Peter Hass; Günther Gademann; Maciej Pech; Jens Ricke
Journal:  Strahlenther Onkol       Date:  2016-02-29       Impact factor: 3.621

Review 5.  Radical irradiation of extracranial oligometastases.

Authors:  Joseph K Salama; Michael T Milano
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

6.  Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Authors:  Jason J Luke; Jeffrey M Lemons; Theodore G Karrison; Sean P Pitroda; James M Melotek; Yuanyuan Zha; Hania A Al-Hallaq; Ainhoa Arina; Nikolai N Khodarev; Linda Janisch; Paul Chang; Jyoti D Patel; Gini F Fleming; John Moroney; Manish R Sharma; Julia R White; Mark J Ratain; Thomas F Gajewski; Ralph R Weichselbaum; Steven J Chmura
Journal:  J Clin Oncol       Date:  2018-02-13       Impact factor: 44.544

Review 7.  Dose to organ at risk and dose prescription in liver SBRT.

Authors:  Rives Michel; Izar Françoise; Parent Laure; Modesto Anouchka; Portier Guillaume; Kirzin Sylvain
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-17

Review 8.  Management of oligometastatic rectal cancer: is liver first?

Authors:  Timur Mitin; C Kristian Enestvedt; Charles R Thomas
Journal:  J Gastrointest Oncol       Date:  2015-04

9.  Stereotactic body radiotherapy for oligoprogressive cancer.

Authors:  Patrick Cheung
Journal:  Br J Radiol       Date:  2016-08-24       Impact factor: 3.039

10.  Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer.

Authors:  Ayman Oweida; Andy Phan; Benjamin Vancourt; Tyler Robin; Mohammad K Hararah; Shilpa Bhatia; Dallin Milner; Shelby Lennon; Laura Pike; David Raben; Bryan Haugen; Nikita Pozdeyev; Rebecca Schweppe; Sana D Karam
Journal:  Thyroid       Date:  2018-06       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.